Regulator Rejects Novartis Heart Failure Drug Fox Business U.S. health regulators turned down an application to approve Novartis' (NAR) experimental heart failure drug due to insufficient evidence that it improves symptoms, the Swiss drugmaker said on Friday. Novartis said in a statement the Food and Drug ... US regulator rejects Novartis heart failure drug FDA Rejects Novel Novartis Drug For Acute Heart Failure FDA Says No to Serelaxin for Heart Failure |
